Hurst C - Search Results

1

Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept.

Neuzillet Y, Mertens L, Shariat S, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B. Neuzillet Y, et al. Among authors: hurst c. Prog Urol. 2014 Nov;24(13):806-7. doi: 10.1016/j.purol.2014.08.054. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461579 French. No abstract available.

2

High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization.

Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA. Hurst CD, et al. Oncogene. 2004 Mar 18;23(12):2250-63. doi: 10.1038/sj.onc.1207260. Oncogene. 2004. PMID: 14968109

3

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. Jebar AH, et al. Among authors: hurst cd. Oncogene. 2005 Aug 4;24(33):5218-25. doi: 10.1038/sj.onc.1208705. Oncogene. 2005. PMID: 15897885

4

DBC1 re-expression alters the expression of multiple components of the plasminogen pathway.

Louhelainen JP, Hurst CD, Pitt E, Nishiyama H, Pickett HA, Knowles MA. Louhelainen JP, et al. Among authors: hurst cd. Oncogene. 2006 Apr 13;25(16):2409-19. doi: 10.1038/sj.onc.1209228. Oncogene. 2006. PMID: 16369496

5

Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway.

Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, Knowles MA. Chapman EJ, et al. Among authors: hurst cd. Oncogene. 2006 Aug 17;25(36):5037-45. doi: 10.1038/sj.onc.1209513. Epub 2006 Apr 17. Oncogene. 2006. PMID: 16619045

6

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

Tomlinson DC, Hurst CD, Knowles MA. Tomlinson DC, et al. Among authors: hurst cd. Oncogene. 2007 Aug 30;26(40):5889-99. doi: 10.1038/sj.onc.1210399. Epub 2007 Mar 26. Oncogene. 2007. PMID: 17384684 Free PMC article.

7

Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.

Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA. Hurst CD, et al. Oncogene. 2008 Apr 24;27(19):2716-27. doi: 10.1038/sj.onc.1210934. Epub 2007 Nov 26. Oncogene. 2008. PMID: 18037967 Free PMC article.

8

A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene.

Hurst CD, Zuiverloon TC, Hafner C, Zwarthoff EC, Knowles MA. Hurst CD, et al. BMC Res Notes. 2009 Apr 29;2:66. doi: 10.1186/1756-0500-2-66. BMC Res Notes. 2009. PMID: 19402901 Free PMC article.

9

Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-immortalized urothelial cells (TERT-NHUC).

Chapman EJ, Williams SV, Platt FM, Hurst CD, Chambers P, Roberts P, Knowles MA. Chapman EJ, et al. Genes Chromosomes Cancer. 2009 Aug;48(8):694-710. doi: 10.1002/gcc.20672. Genes Chromosomes Cancer. 2009. PMID: 19405089

10

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.

Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Platt FM, et al. Clin Cancer Res. 2009 Oct 1;15(19):6008-17. doi: 10.1158/1078-0432.CCR-09-0898. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789314

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

452 results

Search Page

Filters